Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Sur-gery - the Prospective-randomized, Microbiologist-blinded, Stratified, Superiority Trials - BAPTIST Trials

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The perioperative antibiotic prophylaxis is evidence-based in orthopedic surgery. While its duration ranges from a single dose to three doses throughout the world, the choice of the prophylactic agents is undisputed. Worldwide, the surgeons use 1st or 2nd-generation cephalosporins (or vancomycin in some cases). However, there are particular clinical situation with a high risk of antibiotic-resistant surgical site infections (SSI); independently of the duration of adminis-tered prophylaxis. These resistant SSI's occur in contaminated wounds, or during surgery under current therapeutic antibiotics, and base on selection by antibiotics used for therapy or for prophylaxis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years

• Surgery under current or recent therapeutic antibiotics (antibiotic-free window \<14 days and past antibiotic prescription \>4 days)

• Surgery for open fractures and wounds; including 2nd and 3rd looks

• Potentially contaminated wound revision in the operating theatre

• Tumor (oncologic) surgery (if prior radiotherapy and/or bone involvement)

• Spine surgery with ASA-Score \>= 3 points, sacral involvement, or re-vision surgery

• Known skin colonization with multidrug-resistant Gram-negative bacteria

Locations
Other Locations
Switzerland
Balgrist University Hospital
RECRUITING
Zurich
Contact Information
Primary
Ilker Uçkay, Professor
ilker.uckay@balgrist.ch
++41 44 386 37 05
Backup
Mazda Farshad, Professor
mazda.farshad@balgrist.ch
++ 41 44 386 30 00
Time Frame
Start Date: 2022-09-15
Estimated Completion Date: 2025-12-12
Participants
Target number of participants: 1100
Treatments
Active_comparator: Standard prophylaxis arm
The standard prophylaxis consists of one to three intravenous doses of cefuroxime 1.5 g intravenously; or cefuroxim 3g if obesity \> 120 kg or a BMI \> 35 kg/m2; or vancomycin 1 g or clindamycin 600 mg in case of intolerance to cephalosporins~In patients alrady under current therapuetic antibiotic therapy, continuation of that therapuetic antibiotic regimen
Experimental: Innovative prophylaxis arm
Additional single-shot perioperative antibiotic prophylaxis with Broad-spectrum prophylaxis: vancomycin 1 g \& gentamicin 5 mg/kg.
Related Therapeutic Areas
Sponsors
Leads: Balgrist University Hospital

This content was sourced from clinicaltrials.gov